Background
CeTeG/NOA-09 was a phase III randomized open-label trial evaluating the addition of lomustine (CCNU, an alkylating agent) to the standard Stupp regimen (temozolomide + radiation, then adjuvant TMZ) in patients with MGMT-promoter–methylated newly diagnosed GBM. The rationale was that MGMT-methylated tumors are uniquely sensitized to alkylating agents, and combining two alkylating agents (lomustine + TMZ) targeting both DNA-repair mechanisms may synergize in this molecularly selected population. CeTeG/NOA-09 was the first randomized trial specifically targeting MGMT-methylated GBM.
Interventions and follow up
Arm A: Standard Stupp — radiation 60 Gy + concurrent temozolomide 75 mg/m² → adjuvant TMZ 150–200 mg/m² days 1–5 q28d × 6 cycles
Arm B: Radiation 60 Gy + concurrent lomustine 100 mg/m² day 1 + TMZ 100–200 mg/m² days 2–6 → 5 further cycles of lomustine + TMZ q42d
Primary endpoint: Overall survival (OS)
Secondary endpoints: PFS, safety, quality of life
mFollow-up: 33.5 months
Arm B: Radiation 60 Gy + concurrent lomustine 100 mg/m² day 1 + TMZ 100–200 mg/m² days 2–6 → 5 further cycles of lomustine + TMZ q42d
Primary endpoint: Overall survival (OS)
Secondary endpoints: PFS, safety, quality of life
mFollow-up: 33.5 months
Results
mOS: 48.1 vs 31.4 months (HR 0.60, 95% CI 0.35–1.03, P=.0492)
4-yr OS: 46% vs 32%
mPFS: 14.8 vs 11.9 months (HR 0.70, P=.026); 4-yr PFS 25% vs 12%
Subgroup: IDH-wildtype mOS 37.2 vs 22.4 months (HR 0.63)
4-yr OS: 46% vs 32%
mPFS: 14.8 vs 11.9 months (HR 0.70, P=.026); 4-yr PFS 25% vs 12%
Subgroup: IDH-wildtype mOS 37.2 vs 22.4 months (HR 0.63)
Adverse events
Overall: Grade ≥3 AEs 92% vs 56% (substantially higher with LomTMZ); treatment delays 69% vs 9%; discontinuation 30% vs 7%
Hematologic: Grade ≥3 thrombocytopenia 54% vs 4%, leukopenia 57% vs 17%, anemia 8% vs 0%
Hepatic: Grade ≥3 hepatotoxicity 17% vs 10%
Hematologic: Grade ≥3 thrombocytopenia 54% vs 4%, leukopenia 57% vs 17%, anemia 8% vs 0%
Hepatic: Grade ≥3 hepatotoxicity 17% vs 10%
Conclusions
Lomustine plus temozolomide with radiation significantly improved OS (48.1 vs 31.4 months, HR 0.60) compared to the standard temozolomide-based Stupp regimen in MGMT-methylated newly diagnosed GBM, providing proof-of-concept that intensified dual alkylating therapy confers a survival benefit in this molecularly selected population despite substantially higher hematologic toxicity.
Key Limitations
Small sample size (n=141) — underpowered for robust OS analysis (P=.049 marginal); confidence interval crosses 1.0 (HR 0.60, 95% CI 0.35–1.03) raising statistical concerns about the primary endpoint conclusion; high rate of Grade ≥3 hematologic toxicity (thrombocytopenia 54%, leukopenia 57%) with dual alkylation requires intensive monitoring and dose modification; 30% treatment discontinuation in experimental arm limits interpretation; lomustine not widely available in all countries; trial conducted exclusively in Germany; MGMT testing by pyrosequencing (not standard methylation-specific PCR) may not be directly comparable to other trials; no quality-of-life benefit demonstrated; TTFields not used in either arm.
Clinical Context
CeTeG/NOA-09 established lomustine + temozolomide as an option specifically for MGMT-methylated GBM and was incorporated into European (EANO) guidance for fit patients willing to accept the hematologic toxicity. The 48-month median OS is the highest reported in any GBM phase III trial. Together with the CATNON anaplastic-glioma data, CeTeG/NOA-09 highlights the importance of MGMT methylation testing in all newly diagnosed gliomas. Lomustine monotherapy (without TTFields) is also a standard second-line GBM option (EORTC 26101). The practical complexity and toxicity of LomTMZ limit widespread adoption outside academic centers.